Rigel Pharmaceuticals (RIGL) is trading 15% higher at $1.72 today. The stock is quickly outmatching peers on a slightly red day for the Health Care sector.

Rigel Pharmaceuticals has been trading between a 52-week high of $4.24 and a 52-week low of $0.64. The stock has a market cap of $297 Million.

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Here Is How Powerful Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Stock Is
Stocks Register 08-23-22

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) Shares In 2022: Bullish Prospects
Stocks Register 08-19-22

Rigel Pharmaceuticals PT Raised to $2 at Piper Sandler
Investing.com 08-17-22

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL): Blank Check For Growth?
Stocks Register 08-05-22

Rigel rises 17% on strong Q2 result
Seeking Alpha 08-03-22